Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("FABBRO, Doriano")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 16 of 16

  • Page / 1
Export

Selection :

  • and

Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput dockingVANGREVELINGHE, Eric; ZIMMERMANN, Kaspar; SCHOEPFER, Joseph et al.Journal of medicinal chemistry (Print). 2003, Vol 46, Num 13, pp 2656-2662, issn 0022-2623, 7 p.Article

Expression and purification of human recombinant GST-FGF receptor-1HOMANN, Stefanie; SCHACHER, Barbara; ZUMSTEIN-MECKER, Sabine et al.Journal of biotechnology. 2001, Vol 86, Num 1, pp 51-58, issn 0168-1656Article

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412GROWNEY, Joseph D; CLARK, Jennifer J; ADELSPERGER, Jennifer et al.Blood. 2005, Vol 106, Num 2, pp 721-724, issn 0006-4971, 4 p.Article

AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activityTRAXLER, Peter; ALLEGRINI, Peter R; MEYER, Thomas et al.Cancer research (Baltimore). 2004, Vol 64, Num 14, pp 4931-4941, issn 0008-5472, 11 p.Article

Tracing pathway activities with kinase inhibitors and reverse phase protein arrays : Analysis of drug effects and actionsVAN OOSTRUM, Jan; CALENDER, Claudio; RECHSTEINER, Daniel et al.Proteomics. Clinical applications (Print). 2009, Vol 3, Num 4, pp 412-422, issn 1862-8346, 11 p.Article

Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotidesGEIGER, Thomas; HÜSKEN, Dieter; WEILER, Jan et al.Anti-cancer drug design. 2000, Vol 15, Num 6, pp 423-430, issn 0266-9536Article

Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo [2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathwayRECCHIA, Irene; RUCCI, Nadia; FUNARI, Alessia et al.Bone (New York, NY). 2004, Vol 34, Num 1, pp 65-79, issn 8756-3282, 15 p.Article

New sesquiterpene quinols from a micronesian sponge, Aka spMUKKU, Venugopal J. R. V; EDRADA, Ru A; SCHMITZ, Francis J et al.Journal of natural products (Print). 2003, Vol 66, Num 5, pp 686-689, issn 0163-3864, 4 p.Article

Protein kinase C inhibitor and irradiation-induced apoptosis: Relevance of the cytochrome c-mediated caspase-9 death pathwayROCHA, Sonia; SOENGAS, Maria S; LOWE, Scott W et al.Cell growth and differentiation. 2000, Vol 11, Num 9, pp 491-499, issn 1044-9523Article

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivoHOFSTETTER, Barbara; VUONG, Van; BROGGINI-TENZER, Angela et al.Clinical cancer research. 2005, Vol 11, Num 4, pp 1588-1596, issn 1078-0432, 9 p.Article

Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemiaCOOLS, Jan; MENTENS, Nicole; FURET, Pascal et al.Cancer research (Baltimore). 2004, Vol 64, Num 18, pp 6385-6389, issn 0008-5472, 5 p.Article

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4SONI, Rajeev; O'REILLY, Terence; FURET, Pascal et al.Journal of the National Cancer Institute. 2001, Vol 93, Num 6, pp 436-446, issn 0027-8874Article

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KITGLEIXNER, Karoline V; MAYERHOFER, Matthias; PICKL, Winfried F et al.Haematologica (Roma). 2007, Vol 92, Num 11, pp 1451-1459, issn 0390-6078, 9 p.Article

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJING CHEN; LEE, Benjamin H; MOORE, Sandra et al.Oncogene (Basingstoke). 2005, Vol 24, Num 56, pp 8259-8267, issn 0950-9232, 9 p.Article

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinasesWARMUTH, Markus; SIMON, Nicola; MITINA, Olga et al.Blood. 2003, Vol 101, Num 2, pp 664-672, issn 0006-4971, 9 p.Article

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemiasWEISBERG, Ellen; CATLEY, Laurie; HALL-MEYERS, Elizabeth et al.Blood. 2007, Vol 109, Num 5, pp 2112-2120, issn 0006-4971, 9 p.Article

  • Page / 1